Capra Biosciences is a pioneering company in the field of synthetic biology, specializing in the production of high-performance renewable chemicals. The company leverages biofilm technology, which involves thin films of microorganisms that naturally form on surfaces, to create novel and sustainable chemicals. Capra Biosciences operates in the biochemical and pharmaceutical markets, serving clients who require sustainable and cost-efficient chemical solutions. The company's business model revolves around the development and commercialization of these biofilm-based chemicals, making money through the sale of their innovative products. Notably, Capra has developed the first 100% petroleum-free retinol, a form of vitamin A used in anti-aging cosmetics, which is a significant achievement in the cosmetics industry. Additionally, Capra has secured $7.5 million to demonstrate its platform for rapidly scaling pharmaceutical ingredient manufacturing, highlighting its potential for significant impact in the pharmaceutical sector. The company is also part of the BioMaP Consortium Project, which aims to combine sustainable biochemical production with artificial intelligence to create a scalable platform for the quick manufacture of pharmaceutical ingredients. This initiative underscores Capra's commitment to addressing supply chain issues and enhancing national security by reducing dependency on overseas manufacturing.

Keywords: biofilm technology, renewable chemicals, synthetic biology, sustainable production, pharmaceutical ingredients, anti-aging cosmetics, petroleum-free retinol, biochemical market, scalable platform, supply chain security.